Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ Human IL-27 ELISA Kit

Click to view available options
Quantity:
10 x 96 Tests
Description
IL-27 (Interleukin 27) is a cytokine belonging to the IL-12 family, and is a heterodimeric cytokine composed of EBI3 and p28 subunits. IL-27 is produced by activated dendritic cells and macrophages in response to Toll-like receptor ligands and pro-inflammatory cytokines. IL-27 promotes CD4+ T cell differentiation to the Th1 lineage by inducing expression of the transcription factor T-bet and up regulating IL-12R beta2, which in turn suppresses Th2 and Th17 differentiation and proliferation. IL-27 is a recently discovered member of the IL-6/IL-12 family of proinflammatory and immunoregulatory cytokines. IL-27 acts by binding to its receptor WSX-1 and gp130 which results in the activation of a Jak/STAT signaling cascade, suggesting IL-27 involvement in the regulation of immune processes. It has been suggested that IL-27 can also be used as a therapeutic agent against cancer as it can also induce tumor-specific anti-tumor activity mediated through CD8+ T-cells, IFN-gamma, and T-bet. In humans, the gene is located on the p arm of chromosome 16.

Specifications
Specifications
Accession Number | Q14213, Q8NEV9 |
Assay Range | 81 to 20,000 pg/mL |
Assay Sensitivity | 81 pg/mL |
Conjugate | HRP |
Product Type | ELISA |
Sample Type | Plasma, Serum, Supernatant |
For Use With (Equipment) | Colorimetric Microplate Reader |
Gene ID (Entrez) | 10148, 246778 |
Gene Symbol | Ebi3, IL27 |
Interassay CV | <12% |
Show More |
Product Content Correction
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction